Erratum: Impact of Lean Body Mass–Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial

Eric Assenat; Meher Ben Abdelghani; Sophie Gourgou; Hervé Perrier; Faiza Khemissa Akouz; Romain Desgrippes; Marie-Pierre Galais; Chloé Janiszewski; Thibault Mazard; Yves Rinaldi; Côme Lepage; Raphael Tetreau; Pierre Senesse

doi:10.1200/jco-25-02239

Erratum: Impact of Lean Body Mass–Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial

E Eric Assenat M Meher Ben Abdelghani (Medical Oncology Department, ICANS, Strasbourg, France) S Sophie Gourgou H Hervé Perrier F Faiza Khemissa Akouz R Romain Desgrippes M Marie-Pierre Galais C Chloé Janiszewski T Thibault Mazard Y Yves Rinaldi C Côme Lepage (Gastroenterology & Digestive Oncology, Dijon University Hospital Le Bocage, Dijon, France) R Raphael Tetreau P Pierre Senesse

View Original

APA MLA Chicago BibTeX RIS

Article Details

Journal Journal of Clinical Oncology

Volume / Issue Vol. 43, Issue 35

Published December 10, 2025

Pages 3774-3774

DOI 10.1200/jco-25-02239

ISSN 0732-183X

Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (13)

E

Eric Assenat

M

Meher Ben Abdelghani

Medical Oncology Department, ICANS, Strasbourg, France

S

Sophie Gourgou

H

Hervé Perrier

F

Faiza Khemissa Akouz

R

Romain Desgrippes

M

Marie-Pierre Galais

C

Chloé Janiszewski

T

Thibault Mazard

Y

Yves Rinaldi

C

Côme Lepage

Gastroenterology & Digestive Oncology, Dijon University Hospital Le Bocage, Dijon, France

R

Raphael Tetreau

P

Pierre Senesse

Erratum: Impact of Lean Body Mass–Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial

Article Details

Journal Info

Authors (13)

Related Articles from this Journal

Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)

Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer